Is excision alone adequate for low-risk DCIS of the breast treated with breast conserving therapy
- First Online:
- 337 Downloads
Ductal carcinoma in situ (DCIS) represents a quarter of newly diagnosed breast neoplasms, with the majority of cases detected on routine screening mammography in asymptomatic women. Currently, most women with newly diagnosed DCIS are eligible for breast conserving therapy (BCT); however, significant controversy exists regarding whether or not to add radiation treatment (RT) after surgical excision in low-risk patients.
While four older prospective randomized clinical trials have shown that the addition of RT after lumpectomy reduces the risk of ipsilateral breast tumor recurrence (IBTR) by approximately 50 %, recent studies have continued to attempt to identify a subset of patients with favorable risk DCIS who are at a sufficiently low-risk of IBTR that omitting RT might be reasonable. While a number of smaller studies have shown promising results, recent prospective data have consistently affirmed the increased risk of IBTR with the omission of RT, with no subset of patients consistently identified that can be safely observed without RT. While radiation after lumpectomy remains the “standard of care,” even in these low-risk patients, future directions include improvements in genetic assays to better identify low-risk patients and new RT techniques and schedules that can potentially reduce the duration of therapy and toxicity while improving quality of life for patients.
Based on the data available, we continue to recommend radiation therapy for low-risk patients with DCIS as no discernible subset has been identified that does not benefit from radiation therapy.
KeywordsDuctal carcinoma in situ Radiation therapy Excision Breast conserving therapy
- 5.National Comprehensive Cancer Network. Guidelines: breast cancer. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#breast. Accessed August 30, 2012.
- 8.Dean CT, Jubelirer SJ, Plants BA et al (2009) Use of radiation after breast conserving surgery (BCS) for DCIS and early invasive breast cancer at Charleston Area Medical Center (CAMC). A study of compliance with National Comprehensive Center Network (NCCN) guidelines. W V Med J 105:39Google Scholar
- 10.Bijker N, Meijnen P, Peterse JL et al (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma in-situ: ten-Year results of the European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853 — a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24:3381–3387PubMedCrossRefGoogle Scholar
- 16.Julian TV, Land SR, Wang Y, et al. Is boost therapy necessary in the treatment of DCIS? American Society of Clinical Oncology: Breast Symposium. Abstract 146. San Francisco, California, September 7–8, 2007.Google Scholar
- 28.Solin L, Gray R, Baehner FL, et al. A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): a prospective validation study of the DCIS score from ECOG E5194. 34th Annual San Antonio Breast Cancer Symposium. Abstract S4-6. San Antonio, Texas, December 6–10, 2011.Google Scholar
- 30.McCormick B (2012) RTOG 9804: A prospective randomized trial for “good risk” ductal carcinoma in situ (DCIS), comparing radiation (RT) to observation (OBS). J Clin Oncol 30(s):1004Google Scholar
- 31.Hughes KS, Schnaper LA, Cirrincione C et al (2010) Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer. J Clin Oncol 28(s):507Google Scholar
- 35.Silverstein MJ (2003) An argument against routine use of radiotherapy for ductal carcinoma in situ. Oncology (Williston Park) 17:1511–1533Google Scholar
- 42.Mamounas EP, Tang G, Fisher B et al (2010) Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from the NSABP B-14 and NSABP B-20. J Clin Oncol 28:1677–1683PubMedCentralPubMedCrossRefGoogle Scholar
- 43.Tang G, Cuzick J, Constantino JP et al (2011) Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol 29:4365–4372PubMedCentralPubMedCrossRefGoogle Scholar
- 45.Cancer Trials Support Unit: NSABP B-43. https://www.ctsu.org/readfile.aspx?sectionid=31&fname=protocols/nsabp/nsabp-b-43/NSABP_B43_PFS_010612.pdf. Accessed November 5, 2012.
- 50.Vicini F, Shah C, Wilkinson JB, et al (2013) Should ductal carcinoma in situ be removed from the ASTRO cautionary group for off-protocol use of accelerated partial breast irradiation (APBI)? A pooled analysis of outcomes for 300 patients with DCIS treated with APBI. Ann Surg Oncol 20:1275–81Google Scholar
- 52.Vaidya JS, et al. (2012) Targeted intraoperative radiotherapy for early breast cancer: TARGIT-A trial-updated analysis of local recurrence and first analysis of survival. SABCS; Abstract S4-2.Google Scholar
- 54.Bartelink H, Horiot JC, Poortmans PM et al (2007) Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881–10882 trial. J Clin Oncol 25:3259–3265PubMedCrossRefGoogle Scholar
- 55.Romestaing P, Lehinque Y, Carrie C et al (1997) Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon. France J Clin Oncol 15:963–968Google Scholar
- 56.Julian TB, Land SR, Wang Y, et al. Is boost therapy necessary in the treatment of DCIS? http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=52&abstractID=40258. Accessed December 11, 2012.